Lenacapavir injection lowers HIV risk by 96% - AOL
18 hours ago · This corresponds to 99.9% of participants receiving lenacapavir for pre-exposure prophylaxis (PrEP) in the trial not acquiring HIV – translating to a 96% risk reduction compared to the estimated ...
Long-acting injectable lenacapavir proves effective in HIV …
Jul 26, 2024 · WHO welcomes the news that long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women. This represents a significant breakthrough in HIV prevention.
HIV Breakthrough as New Injection 89% More Effective Than PrEP
6 days ago · Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves from catching HIV, but according to a new paper in the New England Journal...
FDA Approves First Injectable Treatment for HIV Pre-Exposure …
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77...
Pre-exposure Prophylaxis - latest research news and features
Mar 28, 2019 · In the U.S., sexual and gender minority populations are disproportionately affected by HIV. Pre-exposure prophylaxis (PrEP) is a key prevention method, but its effectiveness relies on...
Pre-exposure prophylaxis – News, Research and Analysis – The ...
Jul 3, 2024 · Trials have shown that rates of HIV infection are reduced if people not infected with HIV take anti-retrovirals - known as pre-exposure prophylaxis (PrEP). But adherence to a daily dose is...
Final Recommendation Statement: PrEP for HIV Prevention
August 22, 2023 – The U.S. Preventive Services Task Force released today a final recommendation statement on pre-exposure prophylaxis (PrEP) to prevent acquisition of HIV. Healthcare professionals should prescribe PrEP to people at increased risk for HIV.
Long-acting injectable form of HIV prevention outperforms daily pill …
Jul 7, 2020 · HPTN 083 interim results: pre-exposure prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men. Oral presentation at the 23 rd International AIDS …
Pre-Exposure Prophylaxis Access Multifaceted; Unmet Needs …
Oct 16, 2024 · Black, Hispanic and Medicaid-insured populations continue to lack equitable access to pre-exposure prophylaxis, according to new findings from Gilead Sciences presented at IDWeek 2024. Several populations face economic, geographic and …
Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for …
Mar 5, 2024 · The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started using one of them in their second trimester of pregnancy, according to findings presented today at the 2024 Conference on ...